# 510(k) Summary

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

Submitter Name, Address, Contact

Roche Diagnostics   
9115 Hague Road   
P.O. Box 50416   
Indianapolis, IN 46250-0416   
Phone: (317) 521-3577   
Fax: (317) 521-2425   
Email: colleen.adams@roche.com

Contact Person: K. Colleen Adams, Manager US Regulatory Affairs Date Prepared: May 31, 2013

# Device Name

Proprietary name: (1) Elecsys CMV IgG Immunoassay (2) Elecsys PreciControl CMV IgG

# Common name:

(1) CMV IgG PreciControl CMV IgG

Classification name: (1) Enzyme linked immunoabsorbent assay, cytomegalovirus (2) Single (specified) analyte controls (assayed and unassayed)

Product Code: (1)LFZ (JJX

Predicate Device: (1) Diamedix Is-CMV IgG (K981 163) (2) Elecsys PreciControl Rubella IgG (K072617)

# 510(k) Summary, Continued

# Device Description

(1) Elecsys CMV IgG is a two-step sandwich immunoassay with streptavidin microparticles, biotinylated recombinant CMV-specific antigen labeled with a ruthenium complex and electrochemiluminescence detection. The results are determined using a calibration curve which is instrument-specifically generated by a 2-point calibration and a master curve provided via the reagent bar code. Results greater than or equal to $1 . 0 ~ \mathrm { U / m L }$ are considered reactive CMV IgG antibody. The test system contains the human serum-based calibrators intended for use with the system.

(2) Elecsys PreciControl CMV IgG contains liquid control serum based on human serum. The controls are used for monitoring the accuracy of the Elecsys CMV IgG immunoassay.

Note: The reagent and calibrators are packaged together in the Elecsys CMV IgG assay kit, while the associated PreciControl is packaged separately.

Intended   
Use/Indications   
for Use

# Elecsys CMV IgG:

The Elecsys CMV $\overset { \cdot } { \mathrm { I g } } \dot { \mathbf { G } }$ immunoassay is a test for the in vitro semi-quantitative determination of IgG class antibodies to CMV in human serum, lithiumheparin plasma, ${ \bf K } _ { 2 }$ -EDTA plasma, and $\mathrm { K } _ { 3 }$ -EDTA plasma. The test is intended for adults, including expectant mothers, as an aid in presumptive diagnosis of CMV infection. Results with this assay are used to indicate past infection with CMV.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on the indicated Elecsys and cobas e immunoassay analyzers.

This test is not FDA cleared for screening blood or plasma donors.

The performance of this assay has not been established for use in a pediatric population, neonates and immunocompromised patients or for use at point of care facilities.

Elecsys PreciControl CMV IgG: Elecsys PreciControl CMV IgG is used for quality control of the Elecsys CMV IgG immunoassay on the Elecsys and cobas e immunoassay analyzers.

# 510(k) Summary, Continued

# Substantial Equivalence

The Elecsys CMV IgG immunoassay test system is substantially equivalent to other devices legally marketed in the United States.

(1) Elecsys CMV IgG Immunoassay is equivalent to Is-CMV IgG Test System, Diamedix Corporation (K98 1 163).

(2) Elecsys PreciControl CMV IgG is equivalent to the Elecsys PreciControl Rubella IgG (K072617).

# Substantial Equivalence - Comparison

The following tables compare the Elecsys CMV IgG immunoassay and PreciControl CMV IgG with their respective predicate devices.

Continued on next page

# 510(k) Summary, Continued

Comparison of Assays—Similarities and Differences   

<table><tr><td rowspan=1 colspan=3>Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys HSV-2 IgG Reagent andCalibratorCandidate Device)</td><td rowspan=1 colspan=1>Is-CMV IgG Test System(Predicate Device: K981163)</td></tr><tr><td rowspan=1 colspan=3>General Assay Features</td></tr><tr><td rowspan=1 colspan=1>IntendedUselIndicationsfor Use</td><td rowspan=1 colspan=1>The Elecsys CMV IgG immunoassayis a test for the in vitro semi-quantitative determination of IgGclass antibodies to CMV in humanserum, lithium-heparin plasma, K2 -EDTA plasma, and K3 -EDTA plasma.The test is intended for adults,including expectant mothers, as an aidin presumptive diagnosis of CMVinfection. Results with this assay areused to indicate past infection withCMV.</td><td rowspan=1 colspan=1>For the qualitative and semi-quantitative detection of IgGantibodies to cytomegalovirus (CMV)in human serum by indirect enzymeimmunoassay to aid in the assessmentof the patient&#x27;s immunologicalresponse to CMV and to determine theimmune status of individuals,including females of child-bearingage. The evaluation of acute andconvalescent sera can aid in thediagnosis of primary infection,reactivated infection or reinfectionwith CMV. This product is not FDAcleared for use in screening blood andplasma donors.</td></tr><tr><td rowspan=1 colspan=1>AssayProtocol</td><td rowspan=1 colspan=1>Sandwich assay</td><td rowspan=1 colspan=1>Solid phase microtiter</td></tr><tr><td rowspan=1 colspan=1>DetectionProtocol</td><td rowspan=1 colspan=1>ElectrochemiluminescentImmunoassay</td><td rowspan=1 colspan=1>Enzyme-linked immunosorbent assay</td></tr><tr><td rowspan=1 colspan=1>Applications</td><td rowspan=1 colspan=1>18 minutes</td><td rowspan=1 colspan=1>N/A</td></tr></table>

# 510(k) Summary, Continued

Comparison of Assays—Similarities and Differences   

<table><tr><td rowspan=1 colspan=3>Comparison of Assays—Similaritles and Dinferehces</td></tr><tr><td rowspan=1 colspan=3>Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys CMV IgG Reagent andCalibrator(Candidate Device)</td><td rowspan=1 colspan=1>Diamedix Is-CMV IgG(Predicate Device: K981163)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>General Assay Features</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>InstrumentPlatform</td><td rowspan=1 colspan=1>Elecsys 2010, MOduLARANALYTICS E170, cobas e 411,cobas e 601, and cobas e 602</td><td rowspan=1 colspan=1>Automated EIA Processor or Manual</td></tr><tr><td rowspan=1 colspan=1>SampleVolume</td><td rowspan=1 colspan=1>20 μL</td><td rowspan=1 colspan=1>100 μL after dilution</td></tr><tr><td rowspan=1 colspan=1>SampleType</td><td rowspan=1 colspan=1>Human serum and Lithium-heparin,K2-EDTA, and K3-EDTA plasma</td><td rowspan=1 colspan=1>Human whole blood and serum</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Reagents consist of streptavidin-coated microparticles, biotinylatedCMV antigen (recombinant, from E.coli), ruthenylated CMV antigen(recombinant, from E. coli), andnegative and positive calibrators.</td><td rowspan=1 colspan=1>Reagents consist of partially purifiedCMV antigen (AD-169 strainproduced in human fibroblasts)coating the antigen wells.</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Included with the reagent kit</td><td rowspan=1 colspan=1>Included in the reagent kit asDiamedix CMV IgG Standards</td></tr><tr><td rowspan=1 colspan=1>CalibrationInterval</td><td rowspan=1 colspan=1>Calibration must be performed onceper reagent lot using fresh reagent(i.e. not more than 24 hours sincethe reagent kit was registered on theanalyzer). Renewed calibration isrecommended as follows:After 27 days when using thesame reagent lot.After 7 days when using thesame reagent kit on the analyzer.As required: e.g. quality controlfindings with PreciControl CMVIgG outside the defined limits.</td><td rowspan=1 colspan=1>Calibration, using Diamedix CMVIgG Standards, occurs with each useof the antigen wells.</td></tr></table>

# 510(k) Summary, Continued

Comparison of Assays—Similarities and Differences, continued   

<table><tr><td rowspan=1 colspan=3>Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys CMV IgG Reagent andCalibrator(Candidate Device)</td><td rowspan=1 colspan=1>Diamedix Is-CMV IgG(Predicate Device: K981163)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>General Assay Features</td><td rowspan=1 colspan=1>urEs</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Elecsys PreciControl CMV IgG</td><td rowspan=1 colspan=1>High positive, low positive, andnegative controls included in thereagent kit</td></tr><tr><td rowspan=1 colspan=1>Traceability /Standardization</td><td rowspan=1 colspan=1>The Elecsys CMV IgG assay hasbeen standardized against the Rocheinternal standard for CMV IgG. Nointernational standard is availablefor CMV.</td><td rowspan=1 colspan=1>The Diamedix CMV IgG &quot;Standards&quot;(calibrators) are traceable to in-housereference materials and not to anyrecognized national or internationalstandard preparation.</td></tr><tr><td rowspan=1 colspan=1>ReagentStability</td><td rowspan=1 colspan=1>Reagents (ready to use):2-8°C - Up to the statedexpiration dateAfter opening at 2-8°C - 12weeksOn the analyzers — 4 weeksCalibrators (ready to use):Unopened at 2-8°C - Up to statedexpiration dateAfter opening at 2-8°C - 8 weeksOn the Elecsys 2010 and cobas e411 20-25°C - Up to 5 hoursOn the MODULARANALYTICS E170, cobas e 601,and cobas e 602 - Use only once</td><td rowspan=1 colspan=1>Kits and reagents are stable throughtheir expiration dates when stored at 2-8°C.</td></tr><tr><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>The analyzer automaticallycalculates the analyte concentrationof each sample in U/mL.</td><td rowspan=1 colspan=1>Positive, equivocal, or negative resultsare generated by this assayautomatically when utilizing theAutomated EIA Processor.</td></tr></table>

# ${ \bar { 5 } } 1 0 ( \mathbf { k } )$ Summary, Continued

Comparison of Assays—Similarities and Differences, continued   

<table><tr><td rowspan=1 colspan=3>Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys CMV IgG Reagent andCalibrator(Candidate Device)</td><td rowspan=1 colspan=1>Diamedix Is-CMV IgG(Predicate Device: K981163)</td></tr><tr><td rowspan=1 colspan=3>General assay features</td></tr><tr><td rowspan=1 colspan=1>ResultInterpretation</td><td rowspan=1 colspan=1>Results obtained with the ElecyssCMV IgG assay can be interpretedas follows:Non-reactive: &lt; 0.5 U/mLIndeterminate: 0.5 - &lt; 1.0 U/mLReactive: ≥ 1.0 U/mL</td><td rowspan=1 colspan=1>Results of this test are negative,equivocal, or positive for anti-CMVIgG, as defined below:Negative - &lt;8.0 EU/mL,Index &lt; 0.80Equivocal  8.0 to 9.9 EU/mL,Index 0.8 to 0.99Positive - ≥ 10.0 EU/mL,Index ≥ 1.0</td></tr><tr><td rowspan=1 colspan=1>Limits ofMeasurement</td><td rowspan=1 colspan=1>LoB = 0.15 U/mLLoD = 0.25 U/mL</td><td rowspan=1 colspan=1>Not applicable</td></tr><tr><td rowspan=1 colspan=1>Hook Effect</td><td rowspan=1 colspan=1>No hook effect up to 2500 U/mL</td><td rowspan=1 colspan=1>Not tested</td></tr></table>

# 510(k) Summary, Continued

Comparison of Assays—Similarities and Differences, continued   

<table><tr><td colspan="3">milarllles anu Dlerelees. contmiuec</td></tr><tr><td></td><td>Immunoassay Comparison Elecsys CMV IgG Reagent and</td><td>Diamedix Is-CMV IgG (Predicate Device: K981163)</td></tr><tr><td>Feature</td><td colspan="2">Calibrator Candidate Device)</td></tr><tr><td colspan="3">Labeled Performance Characteristies Precision Elecsys 2010 and cobas e 411 Intra-assay/Repeatability:</td></tr><tr><td rowspan="16"></td><td>Negative Control: SD 0.004</td><td>Manual Preparation Intra-assay/Repeatability: Negative Control: SD 0.12 - 0.31 EU/mL Low Control: CV 5.23 - 10.78%</td></tr><tr><td>U/mL Low Control: CV 0.9 - 1.6% High Control: CV 0.7 - 1.4% Serum Samples &lt; 1.0 U/mL: CV 1.5 - 1.9% Serum Samples ≥ 1.0 U/mL: CV 1.2 - 1.5%</td><td>High Control: CV 2.46 - 12.07% Serum Samples &lt; 10.0 EU/mL: SD 0.26 - 2.12 EU/mL Serum Samples ≥ 10.0 EU/mL:</td></tr><tr><td>Intermediate Precision: Negative Control: SD 0.005 U/mL Low Control: CV 3.2 - 3.3% High Control: CV 3.1 - 3.3% Serum Samples &lt; 1.0 U/mL:</td><td>CV 1.03 - 13.90% Intermediate Precision: Negative Control: SD 0.25 - 0.45 EU/mL •Low Control: CV 7.10 - 8.76% High Control: CV 3.41 - 11.00%</td></tr><tr><td>CV 3.2 - 3.4% Serum Samples ≥ 1.0 U/mL: CV 2.6 - 3.9% E170, cobas e 601, and cobas e 602 Intra-assay/Repeatability: Negative Control: SD 0.003</td><td>Serum Samples &lt; 10.0 EU/mL: SD 0.31 - 2.44 EU/mL Serum Samples ≥ 10.0 EU/mL: CV 4.37 - 21.33% Automated Preparation Intra-assay/Repeatability: Negative Control: SD 0.70 EU/mL</td></tr><tr><td>U/mL Low Control: CV 1.0 - 2.0% High Control: CV 1.1 - 1.6% Serum Samples &lt; 1.0 U/mL: CV 1.7% Serum Samples ≥ 1.0 U/mL:</td><td>Low Control: CV 5.05% High Control: CV 8.38% Serum Samples &lt; 10.0 EU/mL: SD 0.43 - 0.56 EU/mL Serum Samples ≥ 10.0 EU/mL: CV 5.39 - 18.07%</td></tr></table>

# 510(k) Summary, Continued

Comparison of Assays—Similarities and Differences, continued   

<table><tr><td rowspan=1 colspan=3>Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys CMV IgG Reagent andCalibrator(Candidate Device)</td><td rowspan=1 colspan=1>Diamedix Is-CMV IgG(Predicate Device: K981163)</td></tr><tr><td rowspan=1 colspan=3>Labeled Performance Characteristics</td></tr><tr><td rowspan=1 colspan=1>Precision(continued)</td><td rowspan=1 colspan=1>Intermediate Precision:Negative Control: SD 0.004U/mLLow Control: CV 3.2 - 4.2%High Control: CV 3.7 - 4.2%Serum Samples &lt; 1.0 U/mL:CV 4.0%Serum Samples ≥ 1.0 U/mL:CV 3.2 - 4.5%</td><td rowspan=1 colspan=1>Intermediate Precision:Negative Control: SD 0.71 EU/mLLow Control: CV 8.77%High Control: CV 6.68%Serum Samples &lt; 10.0 EU/mL:SD 0.54 - 0.74 EU/mLSerum Samples ≥ 10.0 EU/mL:CV 9.43  15.46%</td></tr><tr><td rowspan=1 colspan=1>Cross-Reactivity</td><td rowspan=1 colspan=1>249 samples, which were positivefor the following cross reactants,were tested with the Elecsys CMVIgG and the predicate device:Autoimmune, EBV, E.Coli, HAV,HBV, HCV, HIV, HSV, HTLV,influenza vaccine, rubella, syphilis,and toxoplasmosis. 98.9%agreement was demonstratedbetween the two assays.</td><td rowspan=1 colspan=1>The sponsor tested 47 CMV IgG-negative samples which were positivefor at least one of the followingcrossreactants: VZV IgG, HSV,toxoplasmosis, rubella, EBV, andmeasles. No cross-reactivity wasobserved.</td></tr></table>

# 510(k) Summary, Continued

Comparison of Assays—Similarities and Differences, continued   

<table><tr><td rowspan=1 colspan=3>Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys CMV IgG Reagent andCalibrator(Candidate Device)</td><td rowspan=1 colspan=1>Diamedix Is-CMV IgG(Predicate Device: K981163)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Labeled Performance Characteristics</td><td rowspan=1 colspan=1>cracteristieslowb</td></tr><tr><td rowspan=1 colspan=1>Limitations</td><td rowspan=1 colspan=1>A negative test result does notcompletely rule out the possibilityof an infection with CMV.Individuals may not exhibit anydetectable IgG antibodies at theearly stage of acute infection.The detection of CMV-specificIgG antibodies in a single sampleindicates a previous exposure toCMV but is not always sufficientto distinguish between an acute orlatent infection (irrespective ofthe level of the IgG antibodytiter).In rare cases of primary CMVinfection IgG antibody may bepresent before a specific IgMantibody response is detected. It isrecomimended that a follow-upsample be tested after 2 weeks. Ifthe CMV IgG antibody titerremains stable, a primaryinfection can be excluded.Elecsys CMV IgG results shouldbe used in conjunction with thepatient&#x27;s medical history, clinicalsymptoms and other laboratorytests, e.g. CMV-specific IgMresults, CMV IgG avidity results.</td><td rowspan=1 colspan=1>The results obtained with the Is-CMV IgG Test Kit serve only as anaid to diagnosis and should not beinterpreted as diagnostic inthemselves.Assay performance characteristicshave not been established for visualresult determination.The test should be performed onserum. The use of whole blood orplasma has not been established.The presence of IgG antibodies in asingle serum sample is notsufficient to distinguish betweenactive and past infection. A test forIgM antibodies may be performedfor patients suspected of primaryinfection with CMV.Performance of this assay has notbeen established onspectrophotometry utilizing a singlewavelength.The performance characteristicshave not been established forprenatal populations or newborns.The results on serum fromimmunosuppressed individualsmust be interpreted with caution.</td></tr></table>

# 510(k) Summary, Continued

Comparison of Assays—Similarities and Differences, continued   

<table><tr><td rowspan=1 colspan=3>Olilparlsoll ol Assays</td></tr><tr><td rowspan=1 colspan=3>Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys CMV IgG Reagent andCalibrator(Candidate Device)</td><td rowspan=1 colspan=1>Diamedix Is-CMV IgG(Predicate Device: K981163)</td></tr><tr><td rowspan=1 colspan=2>Labeled Performance Characteristics</td><td rowspan=1 colspan=1>cracteristicsowb</td></tr><tr><td rowspan=1 colspan=1>Limitations,continued</td><td rowspan=1 colspan=1>The results in HIV patients, inpatients undergoingimmunosuppressive therapy, or inpatients with other disordersleading to immune suppression,should be interpreted withcaution.Specimens from neonates, cordblood, pretransplant patients orbody fluids other than serum andplasma, such as urine, saliva oramniotic fluid, have not beentested.There is no high-dose hook effectat CMV IgG concentrations up to2500 U/mL.The assay is unaffected by icterus(bilirubin &lt; 1 129 μmol/L or&lt; 66 mg/dL), hemolysis (Hb&lt; 1000 mg/dL), lipemia(Intralipid &lt; 2000 mg/dL), biotin(&lt; 100 ng/mL) and human serumalbumin (&lt; 20 g/dL). Criterion:Mean recovery of positivesamples within ± 20 % of serumvalue.Samples should not be taken frompatients receiving therapy withhigh biotin doses (i.e. &gt; 5 mg/day)until at least 8 hours following thelast biotin administration.No interference was observedfrom rheumatoid factors up to aconcentration of 1600 IU/mL.</td><td rowspan=1 colspan=1>Studies demonstrating theeffectiveness or monitoring ofantiviral treatments have not beenperformed.Definitive diagnosis of active CMVinfection requires viral isolation.The presence of IgG antibody toCMV does not ensure protectionfrom the disease.The performance characteristics ofthe Diamedix Is-CMV IgG Test Kitwith automated equipment otherthan the MAGO® Plus AutomatedEIA Processor have not beenestablished.</td></tr></table>

# 510(k) Summary, Continued

Comparison of Assays—Similarities and Differences, continued   

<table><tr><td rowspan=1 colspan=3>Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys CMV IgG Reagent andCalibrator(Candidate Device)</td><td rowspan=1 colspan=1>Diamedix Is-CMV IgG(Predicate Device: K981163)</td></tr><tr><td rowspan=1 colspan=3>Labeled Performance Characteristics</td></tr><tr><td rowspan=1 colspan=1>Limitations,continued</td><td rowspan=1 colspan=1>In vitro tests were performed on18 commonly usedpharmaceuticals and in additionon ganciclovir and valganciclovir.No interference with the assaywas found.In rare cases, interference due toextremely high titers of antibodiesto immunological components,streptavidin or ruthenium canoccur. These effects areminimized by suitable test design.For diagnostic purposes, theresults should always be assessedin conjunction with the patient&#x27;smedical history, clinicalexamination and other findings.</td><td rowspan=1 colspan=1>−</td></tr></table>

# 510(k) Summary, Continued

Comparison of Assays—Similarities and Differences, continued   

<table><tr><td colspan="3">Immunoassay Comparison</td></tr><tr><td>Feature</td><td>Elecsys CMV IgG Reagent and Calibrator (Candidate Device)</td><td>Diamedix Is-CMV IgG (Predicate Device: K981163)</td></tr><tr><td colspan="3">Labeled Performance Characteristics Routine Cohort (n=500) Relative Sensitivities to EIA</td></tr><tr><td>Percent Agreement/ Relative Sensitivities and Specificities Positive Percent Agreement (95% CI):</td><td>Positive Percent Agreement (95% CI): 100% (98.7-100%) Negative Percent Agreement (95% Cl): 90.1% (85.3-93.7%) Expectant Mother Cohort (n=98) Positive Percent Agreement (95% CI): 100% (95.4-100%) Negative Percent Agreement (95% Cl): 73.7% (48.8-90.9%)</td><td>Manual (95%CI) Site 1 (n=195): 99.3% (96.3-100.0%) Site 2 (n=168): 96.6% (91.5-99.1%) Site 3 (n=205): 100.0% (97.6-100.0%) Relative Sensitivities to EIA Automated (95% CI) Site 3 (n=201): 100.0% (97.6-100.0%) Relative Specificities to EIA Manual (95% CI) Site 1 (n=195): 97.9% (88.9-99.9%)</td></tr></table>

510(k) Summary, Continued

Comparison of Controls - Similarities and Differences   

<table><tr><td rowspan=1 colspan=3>Comparison of Controis - Similarities and Difierences</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Elecsys PreciControl CMV IgG(Candidate Device)</td><td rowspan=1 colspan=1>Predicate Device:Elecsys PreciControl Rubella IgG(K072617)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>PreciControl CMV IgG is used for thequality control of the Elecsys CMV IgGimmunoassay on the Elecsys and cobas eimmunoassay analyzers.</td><td rowspan=1 colspan=1>Elecsys PreciControl Rubella IgG isused for quality control of the ElecsysRubella IgG immunoassay on theElecsys and cobas e immunoassayanalyzers.</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Three</td><td rowspan=1 colspan=1>Two</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Liquid, ready for use</td><td rowspan=1 colspan=1>Liquid, ready for use</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human serum</td><td rowspan=1 colspan=1>Human serum</td></tr><tr><td rowspan=1 colspan=1>AnalyteConcentration</td><td rowspan=1 colspan=1>PreciControl 0: &lt;0.25 U/mLPreciControl 1: ~1.5 U/mLPreciControl 2: ~25 U/mL</td><td rowspan=1 colspan=1>PreciControl 1: ~4.0 IU/mLPreciControl 2: ~75 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened:.   Store at 2-8°C up to the statedexpiration dateOpened:•  2 - 8°C: 8 weeksOn the Elecsys 2010 and cobas e411 analyzers at 25°C: Up to 5hoursOn the MODULAR ANALYTICSE1 70, cobas e 601, and cobas e 602analyzers 25°C: Up to 2 hours</td><td rowspan=1 colspan=1>Unopened:•   Store at 2-8°C up to the statedexpiration dateOpened:•  2 - 8°C: 8 weeksOn the analyzer at 20-25°C: Upto 5 hours</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>The controls are supplied ready-for-use inbottles compatible with the system. Whenmeasuring non-Roche controls, use onlyrecommended sample tubes, cup on tubeor cup on rack.Elecsys 2010 and cobas e 41 1 analyzers:The original control vials may be used ifthe entire provided volume is used and noaliquots are prepared.The controls should only be lef t on theanalyzer during performance of qualitycontrol. After use, close the bottles assoon as possible ans store upright at 2-8°C. Due to possible evaporation effects,not more than 7 quality controlprocedures per bottle should beperformed.</td><td rowspan=1 colspan=1>The controls are supplied ready-for-usein bottles compatible with the system.The controls should only be left on theanalyzer during performance of qualitycontrol. After use, close the bottles assoon as possible and store upright at 2-8C.Because of possible evaporationeffects, not more than 7 quality controlprocedures per bottle should beperformed.</td></tr></table>

# 510(k) Summary, Continued

# Evaluations Summary

(1) The Elecsys CMV IgG Immunoassay was evaluated for several performance characteristics, including precision, LoB and LoD, high dose hook effect, cross reactivity, method comparison between analyzer platforms, interfering substances, and reagent, calibration, and sample stability.

() The Elecsys PreciControl HSV was evaluated for value assignment and stability.

A summary of the evaluation studies is provided in Section IV.

Additionally, the Elecsy CMV IgG assay was evaluated in a clinical trial using an adult cohort that included specimens from pregnant subjects and CMV IgM-positive subjects.

# February 28, 2014

ROCHE DIAGNOSTICS   
JANE PHILIPS, Ph.D.   
REGULATORY AFFAIRS PROGRAM MANAGER 9115 HAGUE ROAD   
INDIANAPOLIS IN, 46250

Re: K131605 Trade/Device Name: Elecsys CMV IgG Assay and Elecsys PreciControl CMV IgG Regulation Number: 21 CFR 866.3175 Regulation Name: Cytomegalovirus serological reagents Regulatory Class: II Product Code: LFZ, JJX Dated: January 28, 2014 Received: January 29, 2014

Dear Dr. Philips:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809). please contact the Division of Small Manufacturers, International and Consumer   
Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Intermet address http://www.fda.gov/MedicalDevices/ResourcesforYou/lndustry/default.htm. Also. please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803). please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Stephen J. Lovell -S for

Sally A. Hojvat, M.Sc., PhD.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostics and Radiological Health   
Center for Devices and Radiological Health

# Indications for Use Form

S10(k) Number (if known): K131605

Device Name: Elecsys CMV IgG Assay

Indications for Use:

The Elecsys CMV IgG assay is an in vitro qualitative test for the detection of IgG antibodies to CMV in human serum, lithium-heparin plasma, $K _ { \frac { \pi } { 2 } }$ -EDTA plasma, and $\kappa _ { 3 }$ -EDTA plasma. The test is intended as an aid in the determination of the serological status to CMV in individuals in which a CMV IgG test was ordered, including pregnant women.

Performance characteristics have not been evaluated in immunocompromised or immunosuppressed individuals. This test is not intended for use in neonatal screening or for use al point of care facilities. This test is not intended for use in screening blood and plasma donors. The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

Device Name: Elecsys PreciControl CMV lgG

Indications for Use:

Elecsys PreciControl CMV IgG is used for quality control of the Elecsys CMV IgG immunoassay on the Elecsys and cobas e immunoassay analyzers.